Clinical Trial Update: EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus [NA]

View source ↗

Summary

A completed clinical trial evaluated EPA supplementation on vascular inflammation and PON2 gene expression in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Eicosapentaenoic acid (EPA) (eicosapentaenoic acid)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Diabetes Mellitus Type II | NA | Status: COMPLETED